Supernus Pharmaceuticals Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Supernus Pharmaceuticals de 50.5% y 12.1% respectivamente, mientras que el BPA crecerá en un 52.9% al año.
Información clave
50.5%
Tasa de crecimiento de los beneficios
52.86%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.5% |
| Tasa de crecimiento de los ingresos | 12.1% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 06 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 11
SUPN: Easing Supply Constraints Will Support Future Repricing Opportunity
Analysts have inched their price target for Supernus Pharmaceuticals higher to $65, supported by refreshed models that factor in updated fair value estimates, modestly different growth and margin assumptions, and greater confidence that Onapgo supply constraints are easing. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$65 price target as reflecting updated fair value work, where refreshed assumptions on growth and margins support a stronger long-term earnings profile.Actualización de narrativa • Apr 22
SUPN: Resolved Supply Constraints Will Support Future Repricing Potential
Analysts have lifted their price target on Supernus Pharmaceuticals by $5 to $65, citing refreshed models after Q4 results and improved visibility on Onapgo supply as production ramps up with the current supplier and a second source expected in 2027. Analyst Commentary Bullish Takeaways Bullish analysts view the $65 price target, up from $60, as reflecting refreshed forecasts after the latest Q4 update.Actualización de narrativa • Apr 07
SUPN: Resolved Supply Constraints And Dual Sourcing Plans Will Support Future Repricing
Narrative Update: Supernus Pharmaceuticals Analyst Price Target Shift Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are now addressed with increased production capacity and a planned second supplier in 2027. Analyst Commentary Analysts see the updated price target as a reflection of fresh Q4 inputs and improved visibility on Onapgo supply.Actualización de narrativa • Mar 24
SUPN: Resolved Supply Constraints Will Support Repricing Through Improved Execution
Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are easing with increased production capacity and an additional supplier planned for 2027. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated models that better align with recent Q4 information and current expectations for the business.Actualización de narrativa • Mar 10
SUPN: Supply Resolution And Refined P/E Assumptions Will Support Repricing
Analysts have increased their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models following Q4 results and expectations that Onapgo supply constraints are now resolved with expanded production capacity. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated Q4 assumptions that support their view of improved execution and earnings potential.Actualización de narrativa • Feb 23
SUPN: Stable Fair Value And Refined P/E Assumptions Will Support Repricing
Analysts modestly adjusted their $61.33 price target on Supernus Pharmaceuticals as they updated their assumptions around revenue growth, profit margin, and future P/E. This reflects a more finely tuned view of the company’s earnings power and valuation risk.Actualización de narrativa • Feb 09
SUPN: Steady Fair Value And P/E Outlook Will Support Bullish Repricing
Analysts have kept their price target for Supernus Pharmaceuticals broadly steady, citing only modest tweaks to underlying assumptions such as a slightly higher discount rate, minor adjustments to expected revenue growth and profit margin, and a largely unchanged future P/E outlook. Valuation Changes Fair Value Estimate remains unchanged at 61.33.Seeking Alpha • Feb 01
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Summary Supernus remains a Buy, with shares up >50% since mid-2025 and ~25% upside projected for 2026. Qelbree drives growth, with 2026 net sales expected to exceed $450m; patent expirations are being offset by pipeline and acquisitions. The Sage Therapeutics acquisition adds near-term revenue and pipeline depth, though pipeline maturity limits major new launches before 2027. Estimated forward price-to-sales is <4x; cost synergies and incremental pipeline progress support a bullish long-term multi-billion CNS franchise thesis. Read the full article on Seeking AlphaActualización de narrativa • Jan 25
SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have adjusted their price target on Supernus Pharmaceuticals to US$61.33 per share, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E that remain broadly in line with prior estimates. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).Actualización de narrativa • Jan 10
SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have inched their price target on Supernus Pharmaceuticals higher by about $0.83, citing updated assumptions that include a modest adjustment to fair value, slightly different revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).Actualización de narrativa • Dec 19
SUPN: Faster Therapy Adoption Will Drive Shares Toward Higher Future Upside
Analysts have raised their price target on Supernus Pharmaceuticals to $65, up from $40, citing a faster than expected ramp for ONAPGO and the potential for additional upside beyond current peak sales assumptions. Analyst Commentary Recent research updates reflect a constructive shift in sentiment toward Supernus, with multiple firms lifting price targets and emphasizing the upside from ONAPGO's adoption curve.Actualización de narrativa • Dec 05
SUPN: Upgrades Will Drive Future Upside As Revenue Outlook Tightens
Analysts have raised their price target on Supernus Pharmaceuticals to $65 from $40, reflecting growing confidence in stronger ONAPGO uptake and expanded long term earnings potential. Analyst Commentary Recent Street research reflects a more constructive stance on Supernus, with higher price targets supported by improving ONAPGO assumptions and a clearer long term earnings trajectory.Actualización de narrativa • Nov 20
SUPN: Upgrades Will Drive Momentum As Earnings Guidance Increases
Analysts have raised their price target for Supernus Pharmaceuticals from $59.33 to $60.50, citing improved revenue growth expectations and increased peak sales forecasts for ONAPGO. Analyst Commentary Recent Street research reflects growing optimism around Supernus Pharmaceuticals, as analysts adjust their targets and ratings in response to strong expectations for ONAPGO and the company’s broader growth trajectory.Actualización de narrativa • Nov 05
SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk
Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.Actualización de narrativa • Oct 22
Analysts Boost Price Targets for Supernus Pharmaceuticals on Accelerating Growth and Revenue Outlook
Supernus Pharmaceuticals’ analyst price targets have risen sharply, with the fair value estimate increasing from $49.20 to $55.20 per share as analysts cite accelerating growth prospects and higher peak sales potential in key product lines. Analyst Commentary Bullish Takeaways Bullish analysts have raised their price targets substantially, with figures as high as $65 per share.Actualización de narrativa • Oct 08
Widening CNS Access Will Shape Long-term Market Opportunity
Analysts have raised their fair value estimate for Supernus Pharmaceuticals from $40.20 to $49.20, citing a stronger forecast for blockbuster products and higher projected profit margins. This has resulted in a more than $9 increase in their price target.Artículo de análisis • Sep 10
We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Jul 23
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price
Supernus Pharmaceuticals, Inc.'s ( NASDAQ:SUPN ) price-to-sales (or "P/S") ratio of 3.1x might make it look like a buy...Artículo de análisis • May 13
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) just reported healthy earnings but the stock price didn't move much...Artículo de análisis • Feb 10
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking
With a price-to-earnings (or "P/E") ratio of 35.5x Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) may be sending very...Seeking Alpha • Feb 06
Supernus: New Approval Holds Promise Of Increased Growth
Summary Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ONAPGO's market launch in Q2 2025, supported by a robust nurse education program and access support. Continuous subcutaneous apomorphine infusion has a proven 30-year history in Europe, bolstering confidence in ONAPGO's potential success. Supernus' unsteady earnings and unproductive pipeline make it challenging to value, but ONAPGO's approval marks a significant positive development. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Summary Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities. An updated analysis around Supernus Pharmaceuticals is provided in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
With a median price-to-sales (or "P/S") ratio of close to 2.9x in the Pharmaceuticals industry in the United States...
Nueva narrativa • Sep 12
Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics
Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.Seeking Alpha • Sep 12
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Summary Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable. The market may undervalue Supernus, focusing on risks over potential, but strategic M&A and upcoming catalysts like SPN-820 data could drive substantial gains. Read the full article on Seeking AlphaArtículo de análisis • Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ), despite the...Seeking Alpha • Jul 02
Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Summary Supernus' revenue growth is hindered by rapidly declining Trokendi sales. There are no pipeline products reliably poised to help out with revenues. Qelbree provides the one bright point on Supernus' revenues. Read the full article on Seeking AlphaArtículo de análisis • Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
There wouldn't be many who think Supernus Pharmaceuticals, Inc.'s ( NASDAQ:SUPN ) price-to-sales (or "P/S") ratio of...Seeking Alpha • Mar 04
Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Summary Today, we take an updated look at Supernus Pharmaceuticals, Inc. after its posted better-than-expected Q4 results last week. The company will be going through an inflection year in 2024 as one core product faces declining sales while two new compounds see considerable sales growth. Supernus used to 2023 to pay off its convertible note obligations and has a debt-free balance sheet with more than $270 million in cash and marketable securities on it. What is ahead for this biopharma company in 2024. An analysis follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 1,170 | 144 | 343 | 326 | 5 |
| 12/31/2027 | 1,022 | 83 | 223 | 231 | 6 |
| 12/31/2026 | 864 | 25 | 119 | N/A | 6 |
| 3/31/2026 | 777 | -29 | 82 | 83 | N/A |
| 12/31/2025 | 719 | -39 | 46 | 47 | N/A |
| 9/30/2025 | 682 | -19 | 71 | 72 | N/A |
| 6/30/2025 | 665 | 64 | 186 | 187 | N/A |
| 3/31/2025 | 668 | 62 | 163 | 164 | N/A |
| 12/31/2024 | 662 | 74 | 171 | 172 | N/A |
| 9/30/2024 | 652 | 60 | 172 | 173 | N/A |
| 6/30/2024 | 630 | 5 | 154 | 155 | N/A |
| 3/31/2024 | 597 | -16 | 100 | 100 | N/A |
| 12/31/2023 | 608 | 1 | 111 | 111 | N/A |
| 9/30/2023 | 611 | 26 | 93 | 94 | N/A |
| 6/30/2023 | 634 | 43 | 71 | 72 | N/A |
| 3/31/2023 | 668 | 52 | 162 | 162 | N/A |
| 12/31/2022 | 667 | 61 | 116 | 117 | N/A |
| 9/30/2022 | 659 | 38 | 138 | 138 | N/A |
| 6/30/2022 | 630 | 57 | 120 | 120 | N/A |
| 3/31/2022 | 601 | 73 | 94 | 95 | N/A |
| 12/31/2021 | 580 | 53 | 125 | 127 | N/A |
| 9/30/2021 | 564 | 82 | 108 | 110 | N/A |
| 6/30/2021 | 571 | 100 | 117 | 120 | N/A |
| 3/31/2021 | 556 | 111 | 163 | 166 | N/A |
| 12/31/2020 | 520 | 127 | 135 | 138 | N/A |
| 9/30/2020 | 477 | 129 | 145 | 150 | N/A |
| 6/30/2020 | 424 | 118 | 177 | 182 | N/A |
| 3/31/2020 | 402 | 116 | 114 | 119 | N/A |
| 12/31/2019 | 393 | 113 | N/A | 143 | N/A |
| 9/30/2019 | 408 | 106 | N/A | 132 | N/A |
| 6/30/2019 | 409 | 105 | N/A | 157 | N/A |
| 3/31/2019 | 404 | 103 | N/A | 135 | N/A |
| 12/31/2018 | 409 | 111 | N/A | 129 | N/A |
| 9/30/2018 | 381 | 99 | N/A | 132 | N/A |
| 6/30/2018 | 359 | 87 | N/A | 109 | N/A |
| 3/31/2018 | 335 | 73 | N/A | 128 | N/A |
| 12/31/2017 | 302 | 57 | N/A | 115 | N/A |
| 9/30/2017 | 276 | 58 | N/A | 103 | N/A |
| 6/30/2017 | 253 | 104 | N/A | 92 | N/A |
| 3/31/2017 | 228 | 97 | N/A | 83 | N/A |
| 12/31/2016 | 215 | 91 | N/A | 67 | N/A |
| 9/30/2016 | 196 | 84 | N/A | 64 | N/A |
| 6/30/2016 | 179 | 26 | N/A | 35 | N/A |
| 3/31/2016 | 163 | 18 | N/A | 32 | N/A |
| 12/31/2015 | 147 | 14 | N/A | 35 | N/A |
| 9/30/2015 | 135 | 11 | N/A | 18 | N/A |
| 6/30/2015 | 118 | 5 | N/A | 14 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que SUPN sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que SUPN sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que SUPN sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (12.1% al año) de SUPN crezcan más rápidamente que los del mercado US (11.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 12.1% al año) de SUPN crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SUPN se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/25 17:34 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Supernus Pharmaceuticals, Inc. está cubierta por 17 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Emily Bodnar | Berenberg |
| Chi Meng Fong | BofA Global Research |
| Pavan Patel | BofA Global Research |